Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

Phase 3

Completed

Conditions: Myelodysplasia
Lymphoma
Acute Leukemia
Chronic Myelogenous Leukemia (CML)

Interventions: Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate
Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide
Drug: Tacrolimus
Drug: Methotrexate
Drug: Mycophenolate Mofetil
Drug: Cyclophosphamide

First Posted Date: 2019-05-22

Last Posted Date: 2024-04-04

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 431

Registration Number: NCT03959241

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Dana Farber Cancer Institute/Brigham & Women's, Boston, Massachusetts, United States
🇺🇸
Ohio State/Arthur G. James Cancer Hospital, Columbus, Ohio, United States

and more 36 locations

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

Phase 1

Completed

Conditions: Myeloma, Plasma-Cell
Myeloma-Multiple

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rimiducid
Biological: Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells

First Posted Date: 2019-05-22

Last Posted Date: 2021-09-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 13

Registration Number: NCT03958656

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Phase 3

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: pegylated liposomal doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Doxorubicin

First Posted Date: 2019-05-16

Last Posted Date: 2019-05-16

Lead Sponsor: Peking University

Target Recruit Count: 244

Registration Number: NCT03952572

Locations: 🇨🇳
Peking University Cancer Hospital & Institute, Beijing, Beijing, China

High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Phase 2

Completed

Conditions: GVHD

Interventions: Drug: Bortezomib
Drug: Cyclophosphamide

First Posted Date: 2019-05-10

Last Posted Date: 2024-03-07

Lead Sponsor: NYU Langone Health

Target Recruit Count: 23

Registration Number: NCT03945591

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

Early Phase 1

Conditions: Multiple Myeloma

Interventions: Biological: Anti-BCMA CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Immune inhibitors

First Posted Date: 2019-05-09

Last Posted Date: 2021-08-31

Lead Sponsor: Hrain Biotechnology Co., Ltd.

Target Recruit Count: 10

Registration Number: NCT03943472

Locations: 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China

Split-Dose R-CHOP for Older Adults With DLBCL

Phase 2

Active, not recruiting

Conditions: Diffuse Large B Cell Lymphoma
DLBCL
Cancer

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Biological: Pegfilgrastim

First Posted Date: 2019-05-09

Last Posted Date: 2024-12-04

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 26

Registration Number: NCT03943901

Locations: 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

Phase 1

Active, not recruiting

Conditions: Relapsed/Refractory Large B Cell Lymphoma
Relapsed/Refractory Follicular Lymphoma

Interventions: Genetic: ALLO-501
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-05-06

Last Posted Date: 2023-12-01

Lead Sponsor: Allogene Therapeutics

Target Recruit Count: 74

Registration Number: NCT03939026

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
St. Davids South Austin Medical Center, Austin, Texas, United States

and more 4 locations

Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes

Not Applicable

Recruiting

Conditions: Lipodystrophy Acquired
Type1diabetes

Interventions: Drug: Cyclophosphamide

First Posted Date: 2019-05-03

Last Posted Date: 2024-08-14

Lead Sponsor: Children's Hospital of Fudan University

Target Recruit Count: 10

Registration Number: NCT03936829

Locations: 🇨🇳
Children's Hospital of Fudan University, Shanghai, Shanghai, China

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

Phase 2

Conditions: Refractory B Acute Lymphoblastic Leukaemia
Relapsed B Acute Lymphoblastic Leukaemia

Interventions: Biological: CD19 CAR-T CELLS
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2019-05-03

Last Posted Date: 2019-05-06

Lead Sponsor: National University of Malaysia

Target Recruit Count: 10

Registration Number: NCT03937544

Locations: 🇲🇾
UKM Medical Centre, Bandar Tun Razak, Kuala Lumpur, Malaysia

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Phase 2

Withdrawn

Conditions: Metastatic Renal Pelvis Urothelial Carcinoma
Metastatic Ureter Urothelial Carcinoma
Metastatic Urethral Urothelial Carcinoma
Metastatic Bladder Urothelial Carcinoma
Unresectable Renal Pelvis Urothelial Carcinoma
Unresectable Ureter Urothelial Carcinoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Fludarabine Phosphate
Biological: Pembrolizumab
Biological: Autologous Tumor Infiltrating Lymphocytes LN-145
Biological: Aldesleukin

First Posted Date: 2019-05-02

Last Posted Date: 2020-01-02

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT03935347

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy